Replies to post #403032 on NorthWest Biotherapeutics Inc (NWBO)

[Dr Bala]

You can't conclude anything from examples regarding a particular trial.

[biosectinvestor]

Where the results look excellent, the safety profile is excellent but legacy oncology players will be throwing stones from the shadows about different aspects of this trial, and we all know that will be the case whether it is through AF or elsewhere, it won’t matter, the peer review will provide political cover that the FDA is not far out there, and given recent decisions, that can’t be undersold as a benefit for this particular trial, which has consistently looked fantastic and been made to look like a failure, by all the known and usual players.

[biosectinvestor]

Exactly, and not on where there were such incredible safety and other issues. These trials are profoundly different.

[Horseb4CarT]

The peer reviewed paper provides a shield against the bs attacks since the content and conclusions of the paper are in effect validated or at least supported by credible reviewers. This validation of the trial results and their significance must also provide credibility for approval consideration.

[DocLee]

Ex - I've wanted to know for some time, what did you want to be?